Size | Price | |
---|---|---|
500mg | ||
1g | ||
Other Sizes |
Purity: ≥98%
Vinflunine (F 12158, BMS 710485) is a new and semi-synthetic analog of the vinca alkaloid vinorelbine that is bi-fluorinated strucuturally. As a mitotic or tubulin inhibitor, it has anticancer, anti-angiogenic, vascular-disrupting and anti-metastatic properties. The major effects of Vinflunine on dynamic instability are a slowing of the microtubule growth rate, an increase in growth duration, and a reduction in shortening duration. The effects of Vinflunine on the readmilling rate is examined by following [3H]GTP incorporation into MAP-rich microtubules, and the IC50 is 0.42 μM.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Vinflunine displays a linear pharmacokinetic profile in the range of administered doses (from 30 mg/m^2 to 400 mg/m^2) in cancer patients. Fecal excretion accounts for 2/3 of the total elimination of vinflunine and its metabolites and the remaining 1/3 of their elimination indicates urinary excretion. The terminal volume of distribution is large, 2422 ± 676 L (about 35 l/kg), suggesting extensive distribution into tissues. The ratio between plasma and whole blood concentrations of 0.80 ± 0.12. The total blood clearance was 40 L/h according to a population pharmacokinetic analysis in 372 patients. The inter- and intra-individual variability was low, with the coefficient of variation approximately 25% and 8%, respectively. Metabolism / Metabolites The metabolites of influnine are mostly cytochrome P450 3A4, but 4-O-deacetylvinflunine (DVFL) may be slowly formed by multiple esterases. DVFL is the main metabolite and is the only metabolite that retains pharmacological activity. Biological Half-Life The mean terminal half-life is approximately 40 h. The half life of the main metabolite, DVFL, is approximately 120 hours. |
||
Toxicity/Toxicokinetics |
Protein Binding
Vinflunine is 67.2 ± 1.1% bound to human plasma proteins. It mainly binds to high density lipoproteins and serum albumin, and is non-saturable on the range of vinflunine concentrations observed in patients.. Binding to alpha-1 acid glycoprotein and to platelets is negligible (< 5%). |
||
References | |||
Additional Infomation |
Pharmacodynamics
The antitumour effects of vinflunine are dependent on concentration and exposure duration of the drug. Vinflunine mediates an anti-mitotic action by inhibiting the microtubule assembly at micromolar concentrations and reducing the rate and extent of microtubule growing events. _In vivo_, vinflunine displays a significant antitumor activity against a broad spectrum of human xenografts in mice both in terms of survival prolongation and tumour growth inhibition. Compared with other vinca alkaloids, vinflunine is a less-potent inductor of drug resistance _in vitro_. |
Molecular Formula |
C45H54F2N4O8
|
|
---|---|---|
Molecular Weight |
816.93
|
|
Exact Mass |
816.391
|
|
CAS # |
162652-95-1
|
|
Related CAS # |
|
|
PubChem CID |
10629256
|
|
Appearance |
Typically exists as solid at room temperature
|
|
Density |
1.39 g/cm3
|
|
Index of Refraction |
1.652
|
|
LogP |
5.019
|
|
Hydrogen Bond Donor Count |
2
|
|
Hydrogen Bond Acceptor Count |
13
|
|
Rotatable Bond Count |
10
|
|
Heavy Atom Count |
59
|
|
Complexity |
1720
|
|
Defined Atom Stereocenter Count |
9
|
|
SMILES |
CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C(C=C([C@](C4=C5C(C=CC=C6)=C6N4)(CC(C[C@@H](C(F)(F)C)C7)([H])CN7C5)C(OC)=O)C(OC)=C8)=C8N9C)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O
|
|
InChi Key |
NMDYYWFGPIMTKO-HBVLKOHWSA-N
|
|
InChi Code |
InChI=1S/C45H54F2N4O8/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44/h9-14,19-20,26-27,36-38,48,55H,8,15-18,21-24H2,1-7H3/t26-,27-,36+,37-,38-,42-,43-,44+,45+/m1/s1
|
|
Chemical Name |
methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-4-[(12S,14R,16R)-16-(1,1-difluoroethyl)-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8-tetraen-12-yl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.2241 mL | 6.1205 mL | 12.2410 mL | |
5 mM | 0.2448 mL | 1.2241 mL | 2.4482 mL | |
10 mM | 0.1224 mL | 0.6120 mL | 1.2241 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03390504 | ACTIVE, NOT RECRUITING | Drug: Erdafitinib Drug: Vinflunine Drug: Docetaxel |
Urothelial Cancer | Janssen Research& Development, LLC |
2018-03-23 | Phase 3 |
NCT03474107 | ACTIVE, NOT RECRUITING | Drug: Enfortumab Vedotin Drug: Docetaxel Drug: Vinflunine Drug: Paclitaxel |
Bladder Cancer Ureteral Cancer Urothelial Cancer |
Astellas Pharma Global Development, Inc. |
2018-06-27 | Phase 3 |
NCT04527991 | ACTIVE, NOT RECRUITING | Drug:Sacituzumab Govitecan-hziy Drug: Paclitaxel Drug: Docetaxel Drug: Vinflunine |
Locally Advanced or Metastatic Unresectable Urothelial Cancer |
Gilead Sciences | 2021-01-13 | Phase 3 |
NCT03410693 | COMPLETED | Drug:Rogaratinib(BAY1163877) Drug: Chemotherapy |
Carcinoma, Transitional Cell | Bayer | 2018-05-31 | Phase 2 Phase 3 |
NCT02302807 | COMPLETED | Drug: Docetaxel Drug: Paclitaxel Drug: Vinflunine |
Bladder Cancer | Hoffmann-La Roche | 2015-01-13 | Phase 3 |